Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.

Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants